Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05701956
Other study ID # ATTENTION-IV LATE
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 16, 2023
Est. completion date March 2025

Study information

Verified date July 2023
Source The First Affiliated Hospital of University of Science and Technology of China
Contact Wei Hu, MD
Phone +8615155510611
Email andinghu@ustc.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.


Description:

Background and Rationale: Recently, two prospective multicenter RCT (ATTENTION and BAOCHE trials) have shown a significantly beneficial effect of EVT in patients with an acute symptomatic basilar artery occlusion. The EXTEND-IA TNK trial demonstrated that intravenous thrombolysis with tenecteplase is superior to alteplase before EVT for anterior circulation large vessel occlusion strokes. However, it is unclear whether intravenous tenecteplase bridging with EVT is superior to EVT alone in the extended window patients with basilar artery occlusion. Therefore, additional studies are needed to explore the potential benefit of intravenous tenecteplase in these patients. Study design: Multicenter, prospective, controlled clinical trial with open-label treatment and blind outcome assessment (PROBE) of intravenous tenecteplase plus EVT versus EVT alone. The trial has observer blinded assessment of the primary outcome and neuroimaging at baseline and follow up.


Recruitment information / eligibility

Status Recruiting
Enrollment 332
Est. completion date March 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery; 2. Time from stroke onset to randomization within 4.5-24 hours of estimated time of basilar artery occlusion; 3. Patient's age=18 years; 4. Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In cases of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery; 5. Patients presenting with acute ischemic stroke eligible using standard criteria (except for time window) to receive both endovascular thrombectomy and intravenous thrombolysis; 6. Baseline National Institutes of Health Stroke Scale (NIHSS) score= 10 at the time of neuroimaging; 7. The patient or patient's legal representative signs the informed consent form. Exclusion Criteria: 1. CT or MR evidence of intracerebral hemorrhage (the presence of < 10 microbleeds is allowed); 2. Pre-stroke modified Rankin scale (mRS) score of = 2; 3. Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT/ CTA-Source Images<6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) <5; 4. Pregnant or lactating women; 5. Allergy to contrast agent or nitinol alloy; 6. Life expectancy<1 year; 7. CTA/MRA/DSA show vascular tortuosity, vascular variation or artery dissection, which would make it difficult to perform endovascular treatment; 8. Participating in other clinical trials; 9. Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, which cannot be controlled by antihypertensive drugs; 10. Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; or oral anticoagulant with international normalized ratio (INR) > 1.7, or novel oral anticoagulant within prior 48 hours; 11. Blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L), platelet< 100*109/L; 12. Renal insufficiency defined as serum creatinine >2.0 mg/dl (or 176.8 ยต mol/l) or a glomerular filtration rate <30 mL/min or the need for hemodialysis or peritoneal dialysis; 13. Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc); 14. The patient has acute ischemic cerebral infarction within 3 months from randomization; 15. The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis; 16. The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition; 17. CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle; 18. Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination; 19. CTA/MRA/DSA show both anterior and posterior circulation large vessel occlusion; 20. Patients with intracranial tumors (except small meningiomas); 21. Patients who received intravenous thrombolytics treatment before the randomization;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tenecteplase
Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
Procedure:
Endovascular thrombectomy
The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.

Locations

Country Name City State
China The First Affiliated Hospital of University of Science and Technology of China Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of University of Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall mortality at 7 (± 2 days) and 90 (± 14 days) evaluate death rate 7 (± 2 days) and 90 (± 14 days) after procedure
Other Symptomatic intracerebral hemorrhage (sICH) within 72 hours SICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by =4 points than the value at baseline or the lowest value in the first 72 hours or any hemorrhage leading to death Within 72 hours after procedure
Other Any intracerebral hemorrhage within 72 hours Evaluate intracerebral hemorrhage Within 72 hours after procedure
Primary Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days) modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) 90 (± 14 days) after procedure
Secondary Proportion of patients with modified Rankin Score 0-3 at day 90 (±14 days) modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) 90 (± 14 days) after procedure
Secondary Ordinal Shift analysis of modified Rankin Score at day 90 (±14 days) modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) 90 (± 14 days) after procedure
Secondary Score on the NIHSS at 24 hours The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit. 24 hours after procedure
Secondary Score on the NIHSS at 5-7 days or discharge The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit. 5-7 days or discharge after procedure
Secondary Proportion of patients with modified Rankin Score 0-1 at day 90 (±14 days) modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) 90 (± 14 days) after procedure
Secondary Proportion of patients with modified Rankin Score 0-4 at day 90 (±14 days) modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) 90 (± 14 days) after procedure
Secondary Score on the EuroQoL 5-dimensions 5-level (EQ5D-5L) at 90 days (±14 days) Health-related quality of life, assessed with EQ-5D-5L 90 (± 14 days) after procedure
Secondary level of activities of daily living (Barthel index, BI) at 90 days (±14 days) Level of activities of daily living 90 (± 14 days) after procedure
Secondary Successful reperfusion (Extended thrombolysis in cerebral infarction [eTICI] score 2b50-3) on digital substraction angiography (DSA) prior to thrombectomy Evaluate effect of intravenous thrombolysis on reperfusion within 5 minutes at angiography
Secondary Successful reperfusion on final angiography of thrombectomy Evaluate effect of thrombectomy on reperfusion Within 5 minutes at final angiography of thrombectomy
Secondary Successful recanalization on CT or MR angiography within 72 hours Evaluate vascular patency after treatment Within 72 hours after procedure
Secondary Infarct volume (Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score, PC-ASPECTS) evaluated on CT or MRI within 72 hours PC-ASPECTS=10 indicates a normal scan, PC-ASPECTS=0 indicates early ischemic changes or hypoattenuation in all above territories. 1 or 2 points each are subtracted for early ischemic changes or hypoattenuation in: left or right thalamus, cerebellum or posterior cerebral artery territory, respectively (1 point); any part of midbrain or pons (2 points) Within 72 hours after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT01717755 - Basilar Artery International Cooperation Study N/A
Recruiting NCT06101667 - Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) N/A
Recruiting NCT05615038 - A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion N/A
Recruiting NCT05105633 - Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke Phase 2/Phase 3
Recruiting NCT05320263 - Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol N/A
Not yet recruiting NCT04177615 - Randomized Assessment of Rapid Endovascular Treatment in Basilar Artery Occlusion Stroke in 115 Hospital N/A
Recruiting NCT05827042 - Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion Phase 3
Active, not recruiting NCT02737189 - Basilar Artery Occlusion Chinese Endovascular Trial N/A
Not yet recruiting NCT05580822 - Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion Phase 2
Completed NCT04751708 - Endovascular Treatment for Acute Basilar Artery Occlusion N/A
Recruiting NCT05512910 - Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B) Phase 4
Recruiting NCT05402878 - OUTCOME AND SAFETY OF RECANALIZATION TREATMENTS IN ISCHEMIC STROKE DUE TO ACUTE BASILAR ARTERY OCCLUSION
Recruiting NCT05631847 - Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke N/A